Trials to Improve Blood Pressure Through Adherence to Antihypertensives in Stroke/TIA: Systematic Review and Meta-Analysis

Anna De Simoni, PhD; Wendy Hardeman, PhD; Jonathan Mant, MD; Andrew J. Farmer, DM; Ann Louise Kinmonth, MD

Background—The purpose of this study was to determine whether interventions including components to improve adherence to antihypertensive medications in patients after stroke/transient ischemic attack (TIA) improve adherence and blood pressure control.

Methods and Results—We searched MEDLINE, EMBASE, CINAHL, BNI, PsyclINFO, and article reference lists to October 2012. Search terms included stroke/TIA, adherence/prevention, hypertension, and randomized controlled trial (RCT). Inclusion criteria were participants with stroke/TIA; interventions including a component to improve adherence to antihypertensive medications; and outcomes including blood pressure, antihypertensive adherence, or both. Two reviewers independently assessed studies to determine eligibility, validity, and quality. Seven RCTs were eligible (n=1591). Methodological quality varied. All trials tested multifactorial interventions. None targeted medication adherence alone. Six trials measured blood pressure and 3 adherence. Meta-analysis of 6 trials showed that multifactorial programs were associated with improved blood pressure control. The difference between intervention versus control in mean improvement in systolic blood pressure was −5.3 mm Hg (95% CI, −10.2 to −0.4 mm Hg, P=0.035; I²=67% [21% to 86%]) and in diastolic blood pressure was −2.5 mm Hg (−5.0 to −0.1 mm Hg, P=0.046; I²=47% [0% to 79%]). There was no effect on medication adherence where measured.

Conclusions—Multifactorial interventions including a component to improve medication adherence can lower blood pressure after stroke/TIA. However, it is not possible to say whether or not this is achieved through better medication adherence. Trials are needed of well-characterized interventions to improve medication adherence and clinical outcomes with measurement along the hypothesized causal pathway. (J Am Heart Assoc. 2013;2:e000251 doi: 10.1161/JAHA.113.000251)

Key Words: blood pressure • hypertension • prevention • stroke

The number of strokes and their impact on morbidity and mortality continue to increase globally because of population aging, and there is a clear opportunity for better preventive effort.1 Among those who survive a stroke or a transient ischemic attack (TIA), the risk of further stroke is high, ranging from 15% to 42% over 5 years.2,3 Indeed, recurrent stroke accounts for up to 40% of all strokes.4

Recurrent stroke is associated with higher mortality than first stroke, and functional recovery is often poorer,5 so secondary prevention matters. Lowering systolic blood pressure (SBP) by 5 mm Hg or diastolic blood pressure (DBP) by 2.5 mm Hg reduces the incidence of stroke by 15% to 20%, independent of prevalent vascular disease and hypertension.6

However, blood pressure control after stroke is suboptimal, with up to 41% of patients having a SBP >140 mm Hg.7 Blood pressure targets for secondary prevention have been recently lowered to 130/80 mm Hg,8 and some guidelines9 suggest treating all patients with a previous stroke or TIA with antihypertensive medication regardless of blood pressure, unless contraindicated. Patient adherence to antihypertensive therapy is likely to be a major barrier to implementation of these guidelines.10

In primary prevention, a range of interventions to improve adherence have been evaluated. Simplification of dosage regimen improved adherence to antihypertensive drugs although the effect on blood pressure is unclear.11

From the Primary Care Unit, University of Cambridge, United Kingdom (A.D.S., W.H., J.M., A.L.K.); Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom (A.J.F.).

Accompanying Tables S1 through S5 are available at http://jaha.ahajournals.org/content/2/4/e000251/suppl/DC1

Correspondence to: Anna De Simoni, the Primary Care Unit, University of Cambridge, Cambridge, United Kingdom. E-mail: ad550@medschl.cam.ac.uk

Received April 9, 2013; accepted June 12, 2013.

© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an Open Access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

DOI: 10.1161/JAHA.113.000251
significant effects on blood pressure have been reported, notably in the Hypertension Detection and Follow-Up study,12 and an organized system of regular reviews was linked to medication intensification, and medication adherence was not measured.11,13 Evidence remains uncollated for people with stroke who may be particularly motivated but face special challenges in taking their medicines as prescribed. We performed a systematic review of randomized controlled trials of interventions that included a component to improve adherence to antihypertensive drugs in adults with stroke/TIA to assess the impact of these interventions on blood pressure and adherence.

Methods
Eligible studies included adults with confirmed history of stroke/TIA, randomized to interventions including a component to improve adherence to antihypertensive medications and measuring blood pressure or patients’ adherence to antihypertensive medications.

Search Method and Study Selection
We searched Medline (1966 to October 2012), Embase (1980 to October 2012), CINAHL (1981 to October 2012), PsycINFO (1806 to October 2012), and BNI (1985 to October 2012). Search terms covered adherence, prevention, hypertension, clinical terms for TIA/stroke, and terms for randomized controlled trial (search strategy in Table S1). We adapted the search for each database without language restrictions. Reference lists of all included articles were also searched manually.

One reviewer (A.D.S.) screened all titles and abstracts, and 20% were checked independently by W.H., with differences agreed by consensus. The full text was examined for articles in which a definite decision to reject could not be made based on title and abstract alone. Two reviewers (A.D.S. and W.H.) independently assessed all full-text articles, and those not meeting the inclusion criteria by both researchers were excluded.

Two translators assessed foreign-language articles with relevant titles or English abstracts. All translators were familiar with medical literature and terminology. Validation of the data extraction form was performed by A.D.S., W.H., A.L.K., and A.F.

Data Extraction
The data extraction form was created and standardized over 3 meetings between 2 reviewers (A.D.S. and W.H.) until agreement was reached by comparing extractions independently obtained on 3 randomly selected included studies. Two authors (A.D.S., W.H.) independently extracted data on blood pressure and antihypertensive adherence and resolved disagreements through discussion.

A.D.S. and W.H. classified intervention and control strategies independently. They initially used behavior change techniques (BCTs) Taxonomy V114 to identify intervention components, but could not extract meaningful data on BCTs used because of poor reporting, particularly in relation to patient-directed interventions like “education” and “lifestyle.” Therefore, intervention strategies were described more broadly, faithful to the intervention descriptions by the authors. Strategies were grouped into verbal information/advice on disease and secondary-prevention drug treatment, goal setting, supply of printed information/advice material, screening for depression, personalized instructions, and integrated care (see data extraction elements in Table S4).

Quality Assessment
A.D.S. and W.H. appraised each study independently for risk of bias, using accepted guidance.15 We considered sequence generation, allocation concealment, blinding of study personnel and participants, incomplete outcome data, selective outcome reporting, adequacy of the power calculation, and use of intention-to-treat analysis (Table S3).

Statistical Analysis
We calculated pooled effect estimates for systolic blood pressure (SBP) and diastolic blood pressure (DBP) for 6 trials in which these outcomes were reported. We fitted random effects meta-analyses models to allow for heterogeneity between studies in RevMan. We used pooled difference in mean improvement of blood pressure from the intervention together with the pooled difference in mean improvement of blood pressure from the control arms of the trials to estimate the effect of the intervention on blood pressure control. For each analysis, we calculated the $I^2$ statistic to estimate the proportion of the observed variance in effects across studies that indicates real differences rather than random error, with 95% confidence intervals using Stata. We used values of 25%, 50%, and 75% as boundary limits for low, moderate, and high heterogeneity.16 Significance was set at $P<0.05$, and 95% confidence intervals are quoted throughout.

Not all the trials reported the necessary data directly, so we transformed and estimated these as necessary (see Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0).15 If standard deviations of blood pressure measures at follow-up were not supplied,17 we carried forward the baseline values. If the studies reported 95% confidence
intervals only, we calculated standard deviations using the following formula: standard deviation = (confidence interval [CI] × square root [n])/1.96.

For the blood pressure measurements in the meta-analysis, we used data collected at follow-up times. In all studies, blood pressure measurements were recorded at a single follow-up time after the end of the intervention. Follow-ups were carried out straight after the last intervention session in 2 studies, 2 months later in 3 trials, and 3 months later in 1.

We performed sensitivity analyses to explore the impact of excluding:

1. Relatively small studies (with <50 participants per randomization group).
2. Studies considered at high risk of bias.
3. Studies that did not measure adherence.
4. Studies that did not properly describe the adherence component of the intervention.

Three trials included a measure of adherence. The range of outcome measures and the diversity of metrics used to ascertain adherence prevented pooling for meta-analysis.

Results

Study Selection

We included 8 articles referring to 7 separate randomized controlled trials after screening 7518 titles and abstracts and reviewing 48 full texts (Figure 1). Eight trials required further consideration after full-text reading. We excluded 3 studies that made no distinction between adherence to antihypertensive and other medications.

We also excluded 1 study because the primary aim was to improve health professionals’ adherence to prescribing antihypertensives rather than patients’ adherence and 2 further studies in which the outcomes were measured in a population of patients with cardiovascular events that included only a minority of patients.

Figure 1. Study flow. TIA indicates transient ischemic attack.
with stroke.\textsuperscript{27,28} These trials were excluded after contacting the authors and finding that separate outcome measures were not available. We also assessed 2 foreign-language papers, 1 Chinese\textsuperscript{29} and 1 German.\textsuperscript{30} One was excluded as adherence to antihypertensive medication was not measured, and the other study because the intervention was aimed at improving practitioners’ management of blood pressure rather than patients’ adherence.

Eight trials that were identified as potentially eligible were excluded as the results were not available at time of submission (see study characteristics in Table S5).\textsuperscript{31–38}

### Participants’ Characteristics

In 7 trials, 1591 patients living in the community with an average age between 63 and 74 years were randomized. All trials except 1\textsuperscript{39} excluded patients with significant cognitive impairment or with serious comorbidities (see inclusion criteria from Table S2).

Two studies included only patients with a history of stroke, whereas the other 5 had a different proportion of patients with stroke and TIA (Figure 2, Table). The proportion of people with prior diagnosis of hypertension varied from 43\% to 100\%.

Caregivers received the intervention together with patients in 2 studies.\textsuperscript{20,39} Their degree of involvement, though, was not reported.

### Intervention Characteristics

A wide range of interventions were evaluated (Table, Figure 2, and Table S2). All interventions were complex with multiple aims and components that were generally poorly described.

There was considerable variation in terms of size, setting, duration of intervention, and study population (Table and Table S2). Most interventions included ≥4 face-to-face sessions. Primary care doctors and nurses delivered the intervention in 3 studies,\textsuperscript{18–20} pharmacists in 1,\textsuperscript{21} and a researcher in 1.\textsuperscript{22} The intervention was delivered through a computer in 1 study,\textsuperscript{17} and by a written hard-copy “keeping well plan” for patients and evidence-based secondary prevention plan tailored to patients for general practitioners (GPs) in another study.\textsuperscript{39} The interventions were delivered in a variety of settings, including GP surgery, home, and the hospital (Figure 2). Final follow-up was carried out between 0 and 3 months after the last intervention session.

In all studies interventions included information and advice about stroke and the role of preventive drugs. In 5 studies this information and advice were tailored to individual patient characteristics according to their risk factors profile for stroke recurrence. A goal-setting technique was used in 3 studies, with blood pressure targets assigned to patients.\textsuperscript{20–22} Three studies supplied written information.\textsuperscript{18,22,39} Only 1 intervention was explicitly theory based, using social-cognitive theory. This intervention aimed to translate knowledge (of hypertension and its treatment) into effective patient behavior change (improved adherence and BP control), using motivational interviewing.\textsuperscript{22}

Six trials included additional information/advice on treatments other than antihypertensive drugs (cholesterol- and glucose-lowering medications, anticoagulants),\textsuperscript{17,18,20–22,39} and 5 gave information on lifestyle risk factors (eg, smoking cessation, weight reduction).\textsuperscript{17,18,20,22,39}

### Control Interventions

Control groups were described as receiving “usual care” in 4 of 7 studies. In the other studies, control care included generic risk factor advice once from a stroke nurse specialist,\textsuperscript{18} health education from a neurologist,\textsuperscript{17} and advice on healthy lifestyle choices from the multidisciplinary stroke team.\textsuperscript{19}

### Study Quality

Study quality was variable (Table S3). All studies were judged at risk of bias in at least 2 domains, but only 1 study\textsuperscript{21} was judged to be at high risk of bias. Blinding of participants was not possible with these types of intervention. Outcome assessors were clearly blinded to treatment allocation in 3 studies.

### Intervention Effects on Blood Pressure

Six studies\textsuperscript{17–22} examined the effect of interventions on systolic and diastolic blood pressure (Table). Pooled analysis showed that interventions were associated with a significant ($P=0.03$) reduction in SBP of $-5.3$ mm Hg (95\% CI, $-10.2$ to $-0.4$ mm Hg), $I^2=67\%$ (2\% to 86\%). Pooled data on difference in mean DBP showed that interventions were associated with a reduction of $-2.5$ mm Hg (95\% CI, $-5$ to $-0.1$ mm Hg), $I^2=47\%$ (0\% to 79\%); $P=0.05$ (Figure 3).

### Intervention Effect on Adherence to Antihypertensive Medications

The effect of the intervention on patients’ adherence to antihypertensive medications was small and not significant in any of the studies. Adherence was self-reported in 2 studies,\textsuperscript{19,39} undefined in 1,\textsuperscript{17} and assessed from refilling prescription data (persistence of use of antihypertensives) in a further study\textsuperscript{40} (see Table S3). Three trials\textsuperscript{17,19,40} reported on both adherence and blood pressure changes and found no effect on either outcome.
### Table. Information Used for the Analysis of Interventions to Improve Blood Pressure (BP)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Year</th>
<th>Country</th>
<th>Number of Patients</th>
<th>Intervention Content</th>
<th>Delivery</th>
<th>Provider and Settings</th>
<th>Intervention Components as Described in Paper</th>
<th>BP Improvement Intervention (SBP and DBP)</th>
<th>Control (SBP and DBP)</th>
<th>Mean Age of Participants (years)</th>
<th>Average Duration of Intervention / Last Follow-Up (months)</th>
<th>Baseline BP Intervention (SBP and DBP)</th>
<th>Control (SBP and DBP)</th>
<th>Mean (SD)</th>
<th>DOI: 10.1161/JAHA.113.000251</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joubert</td>
<td>2009</td>
<td>Australia</td>
<td>233</td>
<td>Verbal information/ advice on disease/ treatment Personalised instructions Targeting multiple behaviours (adherence-lifestyle) Screening for depression.</td>
<td>Face to face</td>
<td>Telephone</td>
<td>Regular reviews (Pre-discharge education, 6 sessions over 12 months with GP, 6 telephone calls to patients, 6 follow-up telephone calls to GPs) Stroke 85% TIA 15% Primary care physicians Not reported &lt;1 month Not reported</td>
<td></td>
<td></td>
<td></td>
<td>60 C</td>
<td>63 I</td>
<td>12/12</td>
<td>134.2 (17)</td>
<td>76.1 (11.7)</td>
</tr>
<tr>
<td>Adie</td>
<td>2010</td>
<td>UK</td>
<td>56</td>
<td>Verbal information/ advice on disease/ treatment Motivational interviewing Goal setting Targeting multiple behaviours (adherence-lifestyle) Educatve printed material</td>
<td>Phone + written material</td>
<td>Researcher Home</td>
<td>Regular reviews (4 sessions of 20 minutes over 4 months) Minor stroke 57% TIA 43% 12.5% recurrent stroke/TIA &lt;1 month 100% hypertensive</td>
<td></td>
<td></td>
<td></td>
<td>72</td>
<td>4/6</td>
<td>163.7 (19.3)</td>
<td>87.6 (11.4)</td>
<td>167.0 (15.5)</td>
</tr>
<tr>
<td>Chiu</td>
<td>2008</td>
<td>Taiwan</td>
<td>160</td>
<td>Verbal information/ advice on disease/ treatment Goal setting</td>
<td>Face to face</td>
<td>Pharmacists Hospital outpatient</td>
<td>Regular reviews (6 sessions of 1 hour over 6 months) Stroke 48% recurrent stroke &gt;12 months 96% hypertensive</td>
<td></td>
<td></td>
<td></td>
<td>65</td>
<td>6/6</td>
<td>143.5 (19.9)</td>
<td>83.4 (11.8)</td>
<td>142.6 (17.2)</td>
</tr>
<tr>
<td>Ellis</td>
<td>2005</td>
<td>Scotland</td>
<td>205</td>
<td>Verbal information/ advice on disease/ treatment Personalised instructions and patient health records Targeting multiple behaviours (adherence-lifestyle) Educatve printed material</td>
<td>Face to face + written material</td>
<td>Nurses (stroke nurse specialists) Hospital outpatient</td>
<td>Regular reviews (3 sessions of 30 minutes over 3 months) Stroke 68% TIA 32% 31% recurrent stroke/TIA &lt;3 months 70% hypertensive</td>
<td></td>
<td></td>
<td></td>
<td>66 C</td>
<td>64 I</td>
<td>3/5</td>
<td>156.2 (27.2)</td>
<td>83.4 (18.3)</td>
</tr>
</tbody>
</table>

Continued
In 1 trial adherence, defined as missing no fewer than 2 doses in the previous 2 weeks, was the same (98% versus 99%) in both arms; the second trial measured self-reported adherence, and treatment with antihypertensives was 63% and 66% in the intervention and control arms, respectively; 92% of patients in both control and intervention groups were adherent to blood-pressure-lowering medications in the third trial, although the method for measuring this outcome was not reported. Another trial reported persistence with antihypertensive therapy evaluated by comparing medication details at 3-year follow-up, which was 95% and 97% for the intervention and control groups, respectively.

The trials did not use objective measures of adherence (eg, rate of prescription refills, electronic medication monitors) or assess adherence among different classes (eg, calcium antagonists, diuretics, beta-blockers, angiotensin inhibitors).

Sensitivity Analysis of Blood Pressure Outcomes

After exclusion of relatively small studies from the meta-analysis, significant reductions in BP for the intervention care compared with the usual care group were observed (Figure 4A). Pooling data from the studies excluding the study at highest risk of bias showed smaller but still significant improvement in SBP, whereas the effect on DBP was reduced (Figure 4B). A further analysis was performed to check sensitivity to outcome, including only those studies that measured adherence as outcome, failing to detect a difference in either adherence or BP (Figure 4C). A final analysis on studies that fully described the adherence intervention (Figure 4D) showed no effect on SBP/DBP.

**Discussion**

There is little evidence to inform approaches to improve blood pressure control through adherence to antihypertensive drugs among patients with stroke or TIA. A rigorous search discovered only 6 randomized controlled trials of relevant interventions. All included multiple components and together demonstrated clinically important effects on both systolic and diastolic blood pressure. There was no evidence that this effect was a result of improved adherence; few studies measured adherence, and none found an intervention effect.

**Populations**

Populations were highly selected. A third of patients with stroke have difficulty with communication, one fifth of whom suffer from aphasia. Stroke survivors may have
shortened attention spans or may experience deficits in short-term memory, comprehension, or engagement in complex mental activities, requiring behavioral interventions tailored to these impairments.\textsuperscript{43–47} Yet only 1 study\textsuperscript{39} included patients with cognitive deficits and multiple morbidities. Patients with significant communication difficulties were...
largely excluded. Perhaps not surprisingly, therefore, results from this selected population with stroke are consistent with those from similar trials in primary prevention of cardiovascular disease.\textsuperscript{11–13,48}

Only in 1 study\textsuperscript{39} were patients’ ethnicity and social class recorded and primary outcomes adjusted for, with no significant effect on adherence. Patients’ “education” was accounted for in 2 studies.\textsuperscript{17,21} The impact of culture, socioeconomic status, health care coverage systems, and availability of free care and medications was not studied, although likely to have influenced adherence.

### Interventions and Their Delivery

Interventions and their delivery were poorly described. Interventions were commonly adapted from those in studies of primary prevention of cardiovascular disease, including components such as an organized system of regular review, giving patients information or advice on disease and treatment tailored to individual risk factor profiles, goal setting, and motivational interviewing. Although educational interventions were not promising in primary prevention,\textsuperscript{13} they were incorporated into all secondary prevention trials as information and advice on stroke and preventive drug treatments. Yet simplification of the overall drug regimen was not used despite being the most promising strategy to improve adherence to antihypertensive medications in primary prevention trials,\textsuperscript{11} with a study suggesting feasibility in patients with stroke.\textsuperscript{49} Future interventions may use the BCT taxonomy\textsuperscript{14} to aid precise specification of the behavior change techniques used and the criteria defined by the CONSORT statement and Davidson et al\textsuperscript{50} to describe other important intervention components (eg, mode of delivery, fidelity).

There was a surprising lack of attention to epidemiological or qualitative data available to inform interventions that might be more effective with this patient group, perhaps because of the selected study population as detailed above. One qualitative study among patients with stroke identified priorities of longer time for communication, simple language, short sentences and large text, and uncluttered design for written materials.\textsuperscript{51}

Family members or caregivers were only included as recipients of the intervention in 2 trials despite evidence that their involvement improves adherence\textsuperscript{52,53} and that they can find giving medicines difficult.\textsuperscript{54}

Greater attention to physician training in intensification of antihypertensive medication prescribing and simplification of overall drug regimens might also be fruitful. In the effective Hypertension Detection and Follow-Up study, medication intensification rather than adherence was the main target.\textsuperscript{12} It is seldom possible to untangle the effects of intervening on medication adherence from regimen intensification because in most studies patients were advised to see their doctors for medication review if their blood pressure was not at target, and regimen intensification was rarely measured.
Similarly to primary prevention studies, nurse and pharmacist involvement in a whole-systems approach to prescribing might be fruitful. Systems of regular reviews, linked to medication intensification and medication adherence counseling by pharmacists or nurses lead to higher achievement of blood pressure goals (conference abstracts).33,37

Measurement

Measurement of blood pressure and adherence was inconsistent across studies. Where adherence was measured, self-report was used, and objective measures such as pill count devices or electronic monitoring were absent.17,19,39

Interventions showed considerable heterogeneity in terms of design and settings. Despite using appropriate meta-analytic techniques with random-effect models, we were unable to control fully for these differences, and the small number of studies meant that the degree of heterogeneity was uncertain (the confidence interval of $I^2$ ranged from 0% to 86%).

During the period covered by the trials (2002–2011) optimal goals for blood pressure after stroke/TIA changed internationally as well as policies to reinforce them. For example in the United Kingdom the introduction of the quality and outcome frameworks payment to GPs in improving usual care management of risk factors may partially explain the failure to provide evidence of intervention effectiveness in some studies.18,22,39 This could be attributed to improved standards of care received by participants from both arms of the trials.

Given the relatively small number of trials that we identified and their small size (the largest only had 349 participants per randomization group), the small number of studies meant that the degree of heterogeneity was uncertain (the confidence interval of $I^2$ ranged from 0% to 86%).

During the period covered by the trials (2002–2011) optimal goals for blood pressure after stroke/TIA changed internationally as well as policies to reinforce them. For example in the United Kingdom the introduction of the quality and outcome frameworks payment to GPs in improving usual care management of risk factors may partially explain the failure to provide evidence of intervention effectiveness in some studies.18,22,39 This could be attributed to improved standards of care received by participants from both arms of the trials.
participants), publication bias is a concern. It is likely to be negative studies that are not published; therefore, this will not affect our finding that no studies have demonstrated an improvement in adherence, but may mean that we have overestimated the value of multifactorial interventions on blood pressure lowering in this population.

Future Work

Future work should improve on the weaknesses of current evidence, yet review of the designs of 8 additional randomized controlled trial protocols identified by the search strategy, showed little sign of doing so. Trials still excluded participants with significant cognitive and communication impairments; only 2 trial protocols took into account stroke disabilities in the form of adding brief one-on-one sessions or by providing practical problem solving.

Although most protocols measured both blood pressure and adherence, only 1 used the gold standard objective measure of adherence with electronic pill containers. Caregivers were additional recipients of the intervention in only 1 trial protocol for participants with stroke and moderate to severe disabilities. Only 1 trial protocol specified measurement along a hypothesized causal pathway, with other studies continuing to test multifactorial interventions with poorly specified multiple components, with no details of how to isolate their effects on the outcomes measured.

Conclusions

On the basis of the limited data available, there is evidence that multifactorial interventions can be effective in lowering blood pressure in a selected population of patients with stroke or TIA living in the community, although it is not possible to isolate which component(s) of the interventions account for this effect. The effects size is compatible with a 15% to 20% reduction in stroke recurrences.

There is a paucity of studies of interventions to improve medication adherence and blood pressure control after stroke/TIA, when disabilities and cognitive impairment might make adherence particularly difficult.

Future studies should focus on characterizing the target groups that might benefit most from novel or better-applied interventions to improve adherence and include carers as well as patients and a whole healthcare system approach to prescribing and taking medicines. Attention to the reliability and objectivity of adherence and blood pressure measurement is needed. Multifactorial intervention design should enable measurement of intermediate outcomes along a hypothesized causal pathway to allow isolation of active ingredients and cost-effectiveness evaluation of interventions.

Acknowledgments

We thank Isla Kuhn, Reader Services Librarian, University of Cambridge Medical Library, for help developing the search strategy; Professor Stephen Sutton, the Primary Care Unit, University of Cambridge, for helpful advice on interpretation of study heterogeneity and calculation of the CI of $I^2$; Richard Parker, the Primary Care Unit, University of Cambridge, for statistical advice on meta-analysis; and the authors of primary studies included in our review, who responded to requests for clarification or further information about study data.

Sources of Funding

Dr De Simoni was funded by an academic clinical fellowship from the National Institute for Health Research (NIHR) and FSF (Flexibility and Sustainability Funding) from NHS Cambridgeshire at the UK Department of Health. Drs Kinmonth and Farmer are NIHR Senior Investigators. Dr Hardeman's contribution to the study was funded by NIHR Flexibility and Sustainability Funding from NHS Cambridgeshire. Dr Farmer's contribution was funded by NIHR School for Primary Care Research and NIHR Oxford Biomedical Research Consortium.

Disclosures

None.

References


ONLINE DATA-SUPPLEMENT
01. ischemic Attack, transient [MeSH]
02. stroke [MeSH]
03. cerebrovascular disorders [MeSH]
04. stroke* OR poststroke* OR cva* [text word]
05. cerebrovascular* OR cerebral vascular [text word]
05. or/1-5
06. cerebral OR cerebellar OR brain* OR vertebrobasilar [text word]
07. infarct* OR ischaemic* OR ischemic* OR thrombo* OR emboli* OR apoplexy [text word]
08. 6 and 7
09. cerebral OR intracerebral OR intracranial OR brain* OR subarachnoid[text word]
10. haemorrhage OR hemorrhage OR bleed* OR haematoma OR hematoma[text word]
11. 9 and 10
12. 5 or 8 or 11
13. secondary prevention [MeSH]
14. tertiary prevention [MeSH]
15. prevention and control [Subheading]
16. primary prevention [MeSH]
17. or/13-16
18. 12 and 17
19. hypertension [MeSH]
20. antihypertensive agents [MeSH]
22. hypertens* [text word]
23. hypertension [text word]
24. antihypertensive [text word]
25. blood pressure [text word]
26. or/19-25
27. patient compliance [MeSH]
28. compliance* or noncompliance* or non-compliance*[text word]
29. adher* or non-adherence* or nonadherence* [text word]
30. persistence [text word])
31. attitude to health [MeSH]
32. awareness [MeSH]
33. risk factors [MeSH]
34. adverse effects [Subheading]
35. adverse effects [text word]
36. side effects [text word]
37. treatment refusal [MeSH]
38. treatment refusal [text word]
39. refusal or refuse*[text word]
40. dropout* or drop-out* OR drop out*[text word]
41 patient dropouts [MeSH]
42. patient dropouts [text word]
43. patient satisfaction [MeSH]
44. patient satisfaction [text word]
45. secondary prevention [MeSH]
46. secondary prevention [text word]
47. tertiary prevention [MeSH]
48. or/27-47
49. randomized controlled trial [MeSH]
50. controlled clinical trial [MeSH]
51. randomized [text word]
52. placebo [text word]
53. randomly [text word]
54. trial [text word]
55. groups [text word]
56. or/49-55
57. 18 and 26 and 48 and 56

S1 Search Strategy: MEDLINE (PubMed)
<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Aim</th>
<th>Intervention strategies to improve adherence to antihypertensive medications; recipients; control group</th>
<th>Other disease outcomes</th>
<th>Lifestyle outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ade^2010</td>
<td>N= 55, 46% TIA and 54% minor stroke in the previous month. Baseline SBP &gt;140. Excluded patients with dementia, significant disability or co-morbidity. Mean age 71 for control, 74 for intervention, 50% women.</td>
<td>Improving risk factor management in hypertensive patients after stroke/TIA.</td>
<td>Four sessions of 20 minutes over 4 months of telephone counselling by a researcher including: review of hypotensive medications and BP control; supply of tailored educational material; encouragement to see the GP for adjustment of medication if high BP; follow up of agreed goals. The intervention used principles of motivational interviewing to address the core determinants for health behaviour. Through increased knowledge of risks of recurrent stroke and increased self-efficacy patients would choose to improve their medication knowledge and blood pressure control.</td>
<td>Cholesterol</td>
<td>Weight reduction</td>
</tr>
<tr>
<td>C hiu^2008</td>
<td>N= 160 ischemic stroke patients attending stroke clinic &gt;12 months. Mean age 65y, 50% women</td>
<td>Evaluating the adequacy of a pharmacist intervention in improving risk factor management after stroke</td>
<td>6 sessions of 1 hour over 6 months of face to face counselling by a pharmacist in hospital outpatients. Education programme introducing hypotensive drug effects, treatment goals, benefits of therapies, the importance of compliance, verification of drug interactions and reminding of adverse effects.</td>
<td>Cholesterol^2</td>
<td>Exercise increase</td>
</tr>
<tr>
<td>Ellis^2005 McManus^2009 (follow up study)</td>
<td>N= 205, ambulant patients from TIA clinics or ongoing stroke rehabilitation with TIA/stroke in previous 3 months. Excluded patients cognitively impaired. Mean age 66y control and 64y for intervention, 49% women. N = 102 in follow up study</td>
<td>Improving risk factor management, satisfaction, mood and perceived health status after stroke/TIA.</td>
<td>3 sessions of 30 minutes over 3 months of face to face counselling by stroke nurse specialists in hospital outpatients. Patients interviewed and given individual advice on the importance of hypotensive medication compliance and its relevance to secondary prevention. All verbal information backed up by written information. Personalised patient-held records given to patients, detailing their risk factors, and the recommended risk factor targets. This record updated at each visit, and considered a key part of the intervention. Where BP deemed to be at unacceptable levels, patients were encouraged to consult their GPs.</td>
<td>Cholesterol</td>
<td>Smoking cessation</td>
</tr>
<tr>
<td>Hommes^2011</td>
<td>N = 349, first or recurrent stroke, intracerebral haemorrhage,TIA. Excluded patients discharged to nursing homes, cognitive impairment that prevented giving consent, co-morbidities likely to cause death in 2y. Mean age 68y control, 70y intervention, 49% women.</td>
<td>Lowering BP by making patients aware of the importance of BP control and motivating them to see GP regularly in case of hypertension.</td>
<td>4 sessions of 1 hour over 10 months of face to face counselling by study nurse at patient’s home. BP measured by nurse and patients informed of the result, stressing the importance of low BP. If elevated BP, nurse encouraging patient to visit the GP, with letter from the principal investigator with BP value and stressing the importance of lowering BP. Measures to ensure compliance with antihypertensive medications discussed with the patient. Procedure repeated during subsequent visits, patients asked about compliance, GP visits, the results of office BP measurements, and changes in antihypertensive medication.</td>
<td>Number of visits to GP</td>
<td></td>
</tr>
</tbody>
</table>

Outcome measured: BP
Outcome measured: BP^4
Outcome measured: BP and persistence
Outcome measured: BP and adherence

<table>
<thead>
<tr>
<th>Clinical events score</th>
<th>Depression score</th>
<th>HbA1C</th>
<th>Quality of life (EuroQuol)</th>
<th>Rankin score</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglyceride</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting blood glucose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N healthcare contacts.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQ-5D Health Index</td>
<td>Medication knowledge^2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Population</td>
<td>Intervention</td>
<td>Outcome</td>
<td>Control</td>
<td>Measures</td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Joubert et al. 2009</td>
<td>N= 233, TIA and stroke sufferers in the community, without serious co-morbidities. Mean age 68y control and 63y for intervention, 45% women.</td>
<td>Promote the management of vascular risk factors in patients with stroke.</td>
<td>Pre-discharge patient education session on effective management of risk factors (including lifestyle) by nurse coordinator in hospital. Initiation and sustained use of antihypertensive medication treatment. Shared care process explained to GP. GP telephone open access to stroke specialist. Discharge summary detailing relevant investigations, hypotensive medication and planned management. Evidence based recommendations for management of risk factors (including goals, space for recording risk factor data) sent to GPs by nurse coordinator. If best practice not followed by GP, GP contacted by nurse co-ordinator to discuss options. 6 sessions over 12 months of pre-arranged face to face BP consultations for monitoring of BP management in GP surgeries. 6 telephone tracking calls with patient or carer prior to scheduled GP visit by nurse coordinator with semi-structured interviews on current general problems, compliance, management of blood pressure and screening for depression. Information faxed to GP prior to scheduled consultation. 6 follow-up telephone calls with patient or carer after each scheduled GP visit by nurse coordinator to check appropriateness of GP management plan.</td>
<td>Control: usual care.</td>
<td>BP control, adherence.</td>
</tr>
<tr>
<td>Maaslan &amp; 2007</td>
<td>N= 65, TIA, minor stroke or amaurosis fugax in previous 3 months, modified Rankin score &lt;4. Excluded dementia and aphasia sufferers. Mean age 63y control and 65y intervention, 41% women.</td>
<td>Improving the knowledge of patients and risk factor management after stroke/TIA</td>
<td>Individualised Multimedia Computer program (IMCP) showed once (up to 25 minutes) in hospital outpatients. Module containing lay information on hypertension, explanation of the used or prescribed medication and compliance; 2 versions: one version for patients with moderate or large deviations from the desirable level of BP, and a version for those who were already treated for BP. Modules were highly structured and contained combinations of slide shows, background voice and a personal address by one of the researchers. 2 versions: easy (20 minutes with more repetitive elements) and difficult (25 minutes).</td>
<td>To patients.</td>
<td>BP control, adherence.</td>
</tr>
<tr>
<td>Wolfe 2010</td>
<td>N= 523 patients with stroke in previous 6 months. 20%-80 years for control, 22%-80 years for intervention, 47% women.</td>
<td>Overcoming barriers to secondary prevention experienced by patients and practitioners.</td>
<td>Data collection about hypertension, current BP management, including medications prescribed on hospital discharge or within 6 weeks of stroke. Computer generated “keeping well plan” based on data collected, printed and posted to patients and caregivers with evidence-based information and tailored to the patient on strategies to improve BP control including importance of compliance. Computer generated evidence-based secondary prevention plan, printed and emailed/posted to GPs with individual patient risk factors, current risk factor management and relevant UK guidelines on best practice. Up to 3 modified “keeping well plans” generated and posted to patients/care givers and GPs depending upon outpatient</td>
<td>Treatment with antiplatelets, statins, hypoglycaemic anticoagulants</td>
<td>Cholesterol reduction, Lipid profile improvement, Adherence to antiplatelets, Adherence to lipid lowering, Knowledge score at 1 week, Knowledge score at 12 week</td>
</tr>
</tbody>
</table>
S2 Characteristics of the studies included in review. BP indicates blood pressure.
+ Indicates statistical significance.
<table>
<thead>
<tr>
<th>Study</th>
<th>Sequence generation</th>
<th>Concealed allocation</th>
<th>Blinding of participant</th>
<th>Blinding of outcome assessor</th>
<th>Incomplete outcome data</th>
<th>Selective outcome reporting</th>
<th>Adherence</th>
<th>Power calculation</th>
<th>Method used for measuring BP</th>
<th>Method used for measuring adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adie</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>Unclear</td>
<td>no</td>
<td>yes</td>
<td>Blood pressure measured by researcher after 10 minutes seated rest. 12h ambulatory BP was measured with space lab 90207 monitors.</td>
<td></td>
</tr>
<tr>
<td>Chiu</td>
<td>no</td>
<td>Unclear</td>
<td>no</td>
<td>no</td>
<td>Unclear</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>BP: Number of repeated BP measurements not pre-specified (dependent on the discretion of GP and patient).</td>
<td></td>
</tr>
<tr>
<td>Ellis</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>Unclear</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>BP: method not reported.</td>
<td>Persistence with therapy was evaluated by comparing medication details at follow-up, with those documented at completion of the initial study. 95% I, 95% C.</td>
</tr>
<tr>
<td>Ellis</td>
<td>McManus</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
<td>no</td>
<td>BP: method not reported.</td>
<td></td>
</tr>
<tr>
<td>Hornnes</td>
<td>Yes</td>
<td>Yes</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>Unclear</td>
<td>no</td>
<td>yes</td>
<td>BP: 3 measurements in the arm with the highest systolic (SBP) taken at 10 minutes interval. The mean of the last 2 measurements was the baseline BP used for the analysis. UA-787 digital BP monitors calibrated every 12 months.</td>
<td>Adherence: (measured at 1 year follow-up only): patients were classified as compliant if taking all of their doses or missed 1 or 2 doses during the previous 2 weeks. 98% I, 99% C.</td>
</tr>
<tr>
<td>Joubert</td>
<td>yes</td>
<td>Yes</td>
<td>no</td>
<td>Not reported</td>
<td>yes</td>
<td>Unclear</td>
<td>no</td>
<td>Not reported</td>
<td>BP: method not reported.</td>
<td></td>
</tr>
<tr>
<td>Maasland</td>
<td>yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Unclear</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>BP: measured by a calibrated non-invasive semi-continuous measurements with 5-min intervals for 30 minutes.</td>
<td>Adherence: method not reported. 92% I, 92% C.</td>
</tr>
<tr>
<td>Wolfe</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>yes</td>
<td>Adherence</td>
<td>Adherence: self-reported medication use. 128/204 I, 127/191C.</td>
<td></td>
</tr>
</tbody>
</table>

**S3 Quality assessment of included trials and potential sources of bias and reported methods for measuring blood pressure and define adherence. BP indicates blood pressure, C indicates control and I indicates intervention group, respectively.**

Light grey highlights cells with possible biased elements.
Study description.

a) Study Design: type of trial; intervention duration from baseline to final follow up; presence of a theory-base guiding the intervention; intervention being single focus on adherence to antihypertensive/blood pressure or multiple focus with other measured outcomes; method used for measuring adherence/blood pressure, use of adherence/fidelity check to delivery protocols.

b) Participants: number randomized and analyzed at each follow-up; % men; mean and standard deviation of age; country; inclusion and exclusion criteria for recruitment; % stroke and % TIA; % of participants with previous stroke/TIA.

c) Intervention (filled for both intervention and control arms): characteristics of those delivering the intervention; settings; mode of delivery; intensity; duration; description of the intervention; intervention components.

d) Outcomes (for each outcome measured): frequency, description; intervention effect; control effect; statistical significance; statistical test used.

S4 Information used for data extraction from each study.
<table>
<thead>
<tr>
<th>Trial</th>
<th>Year</th>
<th>Country</th>
<th>Number of patients</th>
<th>Intervention Content</th>
<th>Intensity</th>
<th>Multifactorial</th>
<th>Caregivers</th>
<th>Outcome measured</th>
<th>Excluded Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>O’Carroll</td>
<td>2010</td>
<td>UK</td>
<td>n = 60</td>
<td>-formulating better medication-taking routines&lt;br&gt;-personalised instructions&lt;br&gt;-providing evidence for patients’ medication necessity beliefs to outweigh medication concerns beliefs.</td>
<td>2 sessions (2 sessions of 30-45 minutes over 2 weeks)</td>
<td>yes</td>
<td>no</td>
<td>Adherence</td>
<td>(electronic devices)&lt;br&gt;BP&lt;br&gt;No anti-hypertensive medication, aphasia-Frenchay screen &lt;13/20, MMSE &lt;23, using Dosette boxes, not responsible for taking own medication.</td>
</tr>
<tr>
<td>MacKay-</td>
<td>2010</td>
<td>Canada</td>
<td>n=250</td>
<td>-rehabilitative exercise&lt;br&gt;-written health passport&lt;br&gt;-positive reinforcement&lt;br&gt;-adult learning strategies (interactive educational sessions, participant involvement in content selection) &lt;br&gt;-scheduled grocery shopping tours&lt;br&gt;-cooking demonstrations</td>
<td>Regular sessions (2 x75 minutes sessions/week of exercise + 1 x 90 minutes session/week of education over 12 weeks)</td>
<td>yes</td>
<td>No</td>
<td>BP</td>
<td>Family members/caregivers encouraged to attend education sessions.</td>
</tr>
<tr>
<td>Lyons</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>patients with contraindications to exercise testing and training, in accordance with American College of Sports Medicine Guidelines.</td>
</tr>
<tr>
<td>Source</td>
<td>Year</td>
<td>USA</td>
<td>n</td>
<td>Intervention Details</td>
<td>Regular Sessions</td>
<td>SBP</td>
<td>Inclusion Criteria</td>
<td>Exclusion Criteria</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------</td>
<td>-----</td>
<td>---</td>
<td>----------------------</td>
<td>------------------</td>
<td>-----</td>
<td>--------------------</td>
<td>-------------------</td>
<td></td>
</tr>
<tr>
<td>Cheng</td>
<td>2011</td>
<td></td>
<td>268</td>
<td>-group clinics - verbal information/advice on disease/treatment. -self-management of disease -optional one-on-one sessions to individualize and reinforce information</td>
<td>Regular sessions (3 group sessions over 10 month)</td>
<td>yes</td>
<td>No Caregivers encouraged to participate in all aspects of the care intervention</td>
<td>hemorrhagic stroke (due to high short-term mortality rate); unable to actively participate in group clinic as judged by research team (e.g severe global disability); language (aphasia) or cognitive difficulties causing inability to communicate understanding of the study during consent process.</td>
<td></td>
</tr>
<tr>
<td>Dromerick</td>
<td>2011</td>
<td></td>
<td>250</td>
<td>-verbal information/advice on disease/treatment -personalised instructions -motivational interviewing -practical problem solving regarding issues such as transportation, insurance, fear of medication side effects - interaction by navigators with primary care doctors when necessary -assistance in obtaining medications</td>
<td>Regular reviews (2 home visits + monthly telephone sessions over 12 months)</td>
<td>yes</td>
<td>Yes A caregiver or interested party must be available if the participant is moderately/severely disabled.</td>
<td>Severe impairment due to stroke (NIHSS&gt;20); any medical condition that would limit participation in follow up assessments; baseline dementia per informant report (AD 828) or screening assessment (Short Blessed Memory Orientation Concentration Test29).</td>
<td></td>
</tr>
<tr>
<td>Goldfinger</td>
<td>2012</td>
<td></td>
<td>600</td>
<td>-peer education -verbal information/advice on disease/treatment. -self-management of disease -weekly action planning</td>
<td>Regular sessions (1 session/week, 90 minute duration for 6 consecutive weeks),</td>
<td>yes</td>
<td>no</td>
<td>people with severe aphasia or significant cognitive deficits when these conditions would impede participation in a self-management program</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Sample Size</td>
<td>Interventions</td>
<td>Sessions</td>
<td>Adherence</td>
<td>BP Monitoring</td>
<td>BP Control</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>-------------</td>
<td>---------------</td>
<td>----------</td>
<td>------------</td>
<td>---------------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MacKenzie</td>
<td>2011</td>
<td>n=56</td>
<td>- verbal information/advice on disease/treatment. - motivational interviewing - self-monitoring equipment - medication dosettes</td>
<td>Regular sessions (1 telephone follow-up/month over 6 months).</td>
<td>yes</td>
<td>no</td>
<td>BP</td>
<td>Self-reported adherence</td>
<td></td>
</tr>
<tr>
<td>Flemming</td>
<td>2012</td>
<td>n=42</td>
<td>- motivational interviewing - personalised action plan</td>
<td>Regular sessions (3 sessions and 2 telephone follow-up over 12 months)</td>
<td>yes</td>
<td>Not reported</td>
<td>BP</td>
<td>Patients with risk factors under control</td>
<td></td>
</tr>
</tbody>
</table>

**S5** Trials identified by the search strategy of which results have not yet been published.

BP and SBP indicates blood pressure, respectively.
Reference list


8 Wolfe CD, Redfern J, Rudd AG, Grieve AP, Heuschmann PU, McKevitt C. Cluster randomized controlled trial of a patient and general practitioner intervention to improve the


prevent recurrence of all inner-city strokes through education randomized controlled trial.


Trials to Improve Blood Pressure Through Adherence to Antihypertensives in Stroke/TIA: Systematic Review and Meta-Analysis

Anna De Simoni, Wendy Hardeman, Jonathan Mant, Andrew J. Farmer and Ann Louise Kinmonth

*J Am Heart Assoc.* 2013;2:e000251; originally published August 20, 2013;
doi: 10.1161/JAHA.113.000251

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/2/4/e000251

Data Supplement (unedited) at:
http://jaha.ahajournals.org/content/suppl/2013/08/23/jah3262.DC1
01. ischemic Attack, transient [MeSH]
02. stroke [MeSH]
03. cerebrovascular disorders [MeSH]
04. stroke* OR poststroke* OR cva* [text word]
05. cerebrovascular* OR cerebral vascular [text word]
05. or/1-5
06. cerebral OR cerebellar OR brain* OR vertebrobasilar [text word]
07. infarct* OR ischaemic* OR ischemic* OR thrombo* OR emboli* OR apoplexy [text word]
08. 6 and 7
09. cerebral OR intracerebral OR intracranial OR brain* OR subarachnoid[text word]
10. haemorrhage OR hemorrhage OR bleed* OR haematoma OR hematoma[text word]
11. 9 and 10
12. 5 or 8 or 11
13. secondary prevention [MeSH]
14. tertiary prevention [MeSH]
15. prevention and control [Subheading]
16. primary prevention [MeSH]
17. or/13-16
18. 12 and 17
19. hypertension [MeSH]
20. antihypertensive agents [MeSH]
22. hypertens* [text word]
23. hypertension [text word]
24. antihypertensive [text word]
25. blood pressure [text word]
26. or/19-25
27. patient compliance [MeSH]
28. compliance* or noncompliance* or non-compliance*[text word]
29. adher* or non-adherence* or nonadherence* [text word]
30. persistence [text word])
31. attitude to health [MeSH]
32. awareness [MeSH]
33. risk factors [MeSH]
34. adverse effects [Subheading]
35. adverse effects [text word]
36. side effects [text word]
37. treatment refusal [MeSH]
38. treatment refusal [text word]
39. refusal or refuse*[text word]
40. dropout* or drop-out* OR drop out*[text word]
41. patient dropouts [MeSH]
42. patient dropouts [text word]
43. patient satisfaction [MeSH]
44. patient satisfaction [text word]
45. secondary prevention [MeSH]
46. secondary prevention [text word]
47. tertiary prevention [MeSH]
48. or/27-47
49. randomized controlled trial [MeSH]
50. controlled clinical trial [MeSH]
51. randomized [text word]
52. placebo [text word]
53. randomly [text word]
54. trial [text word]
55. groups [text word]
56. or/49-55
57. 18 and 26 and 48 and 56

S1 Search Strategy: MEDLINE (PubMed)
<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Aim</th>
<th>Intervention strategies to improve adherence to antihypertensive medications; recipients; control group</th>
<th>Other disease outcomes</th>
<th>Lifestyle outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aide 2010</td>
<td>N= 56, 46% TIA and 54% minor stroke in the previous month. Baseline SBP &gt;140. Excluded patients with dementia, significant disability or co-morbidity. Mean age 71 for control, 74 for intervention, 50% women.</td>
<td>Improving risk factor management in hypertensive patients after stroke/TIA.</td>
<td>Four sessions of 20 minutes over 4 months of telephone counselling by a researcher including: review of hypotensive medications and BP control; supply of tailored educational material; encouragement to see the GP for adjustment of medication if high BP; follow up of agreed goals. The intervention used principles of motivational interviewing to address the core determinants for health behaviour. Through increased knowledge of risks of recurrent stroke and increased self-efficacy patients would choose to improve their medication knowledge and blood pressure control.</td>
<td>Cholesterol, Rankin score</td>
<td>Weight reduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Outcome measured: BP</td>
<td>To patients.</td>
<td>EQ-5D Health Index</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Control: usual care</td>
<td></td>
<td>Medication knowledge+</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N healthcare contacts.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chiu 2008</td>
<td>N= 160 ischemic stroke patients attending stroke clinic &gt;12 months. Mean age 65y, 50% women</td>
<td>Evaluating the adequacy of a pharmacist intervention in improving risk factor management after stroke</td>
<td>6 sessions of 1 hour over 6 months of face to face counselling by a pharmacist in hospital outpatients. Education programme introducing hypotensive drug effects, treatment goals, benefits of therapies, the importance of compliance, verification of drug interactions and reminding of adverse effects.</td>
<td>Cholesterol, LDL, Triglyceride, Fasting blood glucose</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Outcome measured: BP</td>
<td>To patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Control: usual care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ellis 2005</td>
<td>N= 205, ambulant patients from TIA clinics or ongoing stroke rehabilitation with TIA/stroke in previous 3 months. Excluded patients cognitively impaired. Mean age 66y control and 64y for intervention, 49% women. N = 102 in follow up study</td>
<td>Improving risk factor management, satisfaction, mood and perceived health status after stroke/TIA.</td>
<td>3 sessions of 30 minutes over 3 months of face to face counselling by stroke nurse specialists in hospital outpatients. Patients interviewed and given individual advice on the importance of hypotensive medication compliance and its relevance to secondary prevention. All verbal information backed up by written information. Personalised patient-held records given to patients, detailing their risk factors, and the recommended risk factor targets. This record updated at each visit, and considered a key part of the intervention. Where BP deemed to be at unacceptable levels, patients were encouraged to consult their GPs.</td>
<td>Cholesterol, Hba1C, Quality of life (EuroQuol), Depression score, Clinical events incidence at 3y follow-up</td>
<td>Smoking cessation</td>
</tr>
<tr>
<td>McManus 2009</td>
<td></td>
<td>Outcome measured: BP and persistence</td>
<td>To patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(follow up study)</td>
<td></td>
<td>Control: usual care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homnes 2011</td>
<td>N = 349, first or recurrent stroke, intracerebral haemorrhage,TIA. Excluded patients discharged to nursing homes, cognitive impairment that prevented giving consent, co-morbidities likely to cause death in 2y. Mean age 68y control, 70y intervention, 49% women.</td>
<td>Lowering BP by making patients aware of the importance of BP control and motivating them to see GP regularly in case of hypertension.</td>
<td>4 sessions of 1 hour over 10 months of face to face counselling by study nurse at patient’s home. BP measured by nurse and patients informed of the result, stressing the importance of low BP. If elevated BP, nurse encouraging patient to visit the GP, with letter from the principal investigator with BP value and stressing the importance of lowering BP. Measures to ensure compliance with antihypertensive medications discussed with the patient. Procedure repeated during subsequent visits, patients asked about compliance, GP visits, the results of office BP measurements, and changes in antihypertensive medication.</td>
<td>Number of visits to GP</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Outcome measured: BP and adherence</td>
<td>To patients.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Control: usual care</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Outcome Measures:**
- **Blood Pressure (BP)**: measured at baseline, post-intervention, and follow-up.
- **Cholesterol**
- **Hba1C**: glycated hemoglobin
- **Quality of Life**: measured using EQ-5D and EuroQuol
- **Depression Score**: measured using the PHQ-9
- **Clinical Events**: incidence rate
- **Number of Visits to GP**: count of GP visits

**Other Interventions:**
- **Behavioral Counseling**: to improve adherence to antihypertensive medications.
- **Physical Activity**: encouraged through counseling and individual advice.
- **Healthy Lifestyle Choices**: advice on smoking cessation, diet, and exercise.

**Study Designs:**
- **Randomized Controlled Trials**
- **Prospective Cohort Studies**
- **Case-Control Studies**
- **Cross-Sectional Studies**

**Follow-Up Periods:**
- **3 Months**
- **6 Months**
- **12 Months**
- **24 Months**

**Intervention Modalities:**
- **Face-to-Face Counseling**
- **Telephone Counseling**
- **Web-based Interventions**
- **Pharmacist-Managed Interventions**

**Outcome Endpoints:**
- **Blood Pressure Control**: defined as BP <140/90 mmHg.
- **Mortality**: all-cause mortality.
- **Cardiovascular Events**: recurrent stroke, TIA, myocardial infarction.
- **Quality of Life**: measured using EQ-5D and EuroQuol.
- **Depression**: measured using the PHQ-9.
<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Condition</th>
<th>Intervention</th>
<th>Outcome</th>
<th>Control</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joubert et al. 2009</td>
<td>233, TIA and stroke sufferers in the community, without serious co-morbidities. Mean age 68y control and 63y for intervention, 45% women.</td>
<td>Promote the management of vascular risk factors in patients with stroke.</td>
<td>Pre-discharge patient education session on effective management of risk factors (including lifestyle) by nurse coordinator in hospital. Initiation and sustained use of antihypertensive medication treatment. Shared care process explained to GP. GP telephone open access to stroke specialist. Discharge summary detailing relevant investigations, hypotensive medication and planned management. Evidence based recommendations for management of risk factors (including goals, space for recording risk factor data) sent to GPs by nurse coordinator. If best practice not followed by GP, GP contacted by nurse co-ordinator to discuss options. 6 sessions over 12 months of pre-arranged face to face GP consultations for monitoring of BP management in GP surgeries. 6 telephone tracking calls with patient or carer prior to scheduled GP visit by nurse coordinator with semi-structured interviews on current general problems, compliance, management of blood pressure and screening for depression. Information faxed to GP prior to scheduled consultation. 6 follow-up telephone calls with patient or carer after each scheduled GP visit by nurse coordinator to check appropriateness of GP management plan. To patients, GPs.</td>
<td>Control: usual care.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maaslan d et al. 2007</td>
<td>65, TIA, minor stroke or amaurosis fugax in previous 3 months, modified Rankin score &lt;4. Excluded dementia and aphasia sufferers. Mean age 63y control and 65y intervention, 41% women.</td>
<td>Improving the knowledge of patients and risk factor management after stroke/TIA</td>
<td>Individualised Multimedia Computer program (IMCP) showed once (up to 25 minutes) in hospital outpatients. Module containing lay information on hypertension, explanation of the used or prescribed medication and compliance; 2 versions: one version for patients with moderate or large deviations from the desirable level of BP, and a version for those who were already treated for BP. Modules were highly structured and contained combinations of slide shows, background voice and a personal address by one of the researchers. 2 versions: easy (20 minutes with more repetitive elements) and difficult (25 minutes).</td>
<td>Control: routine care including standard health education by neurologist.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wolfe et al. 2010</td>
<td>523 patients with stroke in previous 6 months. 20%-80 years for control, 22%-80 years for intervention, 47% women</td>
<td>Overcoming barriers to secondary prevention experienced by patients and practitioners.</td>
<td>Data collection about hypertension, current BP management, including medications prescribed on hospital discharge or within 6 weeks of stroke. Computer generated “keeping well plan” based on data collected, printed and posted to patients and caregivers with evidence-based information and tailored to the patient on strategies to improve BP control including importance of compliance. Computer generated evidence-based secondary prevention plan, printed and emailed/posted to GPs with individual patient risk factors, current risk factor management and relevant UK guidelines on best practice. Up to 3 modified “keeping well plans” generated and posted to patients/care givers and GPs depending upon outpatient</td>
<td>Control: usual care.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
S2 Characteristics of the studies included in review. BP indicates blood pressure.

* Indicates statistical significance.
<table>
<thead>
<tr>
<th>Study</th>
<th>Sequence generation</th>
<th>Concealed allocation</th>
<th>Blinding of participant</th>
<th>Blinding of outcome assessor</th>
<th>Incomplete outcome data</th>
<th>Selective outcome reporting</th>
<th>Potential threats to validity</th>
<th>Power calculation</th>
<th>Method used for measuring BP</th>
<th>Method used for measuring adherence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adie²</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>Unclear</td>
<td>no</td>
<td>yes</td>
<td>Blood pressure measured by researcher after 10 minutes seated rest. 12h ambulatory BP was measured with space lab 90207 monitors.</td>
<td></td>
</tr>
<tr>
<td>Chiu²</td>
<td>no</td>
<td>Unclear</td>
<td>no</td>
<td>no</td>
<td>Unclear</td>
<td>no</td>
<td>Not reported</td>
<td>BP: Number of repeated BP measurements not pre-specified (depended on the discretion of GP and patient).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ellis²</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>Unclear</td>
<td>no</td>
<td>yes</td>
<td>BP: method not reported. Persistence with therapy was evaluated by comparing medication details at follow-up, with those documented at completion of the initial study. 95% I, 95% C.</td>
<td></td>
</tr>
<tr>
<td>McManus ²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hornnes²</td>
<td>Yes</td>
<td>Yes</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
<td>yes</td>
<td>BP: 3 measurements in the arm with the highest systolic (SBP) taken at 10 minutes interval. The mean of the last 2 measurements was the baseline BP used for the analysis. UA-787 digital BP monitors calibrated every 12 months. Adherence: (measured at 1 year follow up only): patients were classified as compliant if taking all of their doses or missed 1 or 2 doses during the previous 2 weeks. 98% I, 99% C.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joubert²</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>Not reported</td>
<td>yes</td>
<td>Unclear</td>
<td>Not reported</td>
<td>BP: method not reported.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maasland 7</td>
<td>yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>yes</td>
<td>BP: measured by a calibrated non-invasive semi-continuous measurements with 5-min intervals for 30 minutes. Adherence: method not reported. 92% I, 92% C.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wolfe³</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>yes</td>
<td>Adherence: self-reported medication use. 128/204 I, 127/191C.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

S3 Quality assessment of included trials and potential sources of bias and reported methods for measuring blood pressure and define adherence. BP indicates blood pressure, C indicates control and I indicates intervention group, respectively. Light grey highlights cells with possible biased elements.
Study description.

a) Study Design: type of trial; intervention duration from baseline to final follow up; presence of a theory-base guiding the intervention; intervention being single focus on adherence to antihypertensive/blood pressure or multiple focus with other measured outcomes; method used for measuring adherence/blood pressure, use of adherence/fidelity check to delivery protocols.

b) Participants: number randomized and analyzed at each follow-up; % men; mean and standard deviation of age; country; inclusion and exclusion criteria for recruitment; % stroke and % TIA; % of participants with previous stroke/TIA.

c) Intervention (filled for both intervention and control arms): characteristics of those delivering the intervention; settings; mode of delivery; intensity; duration; description of the intervention; intervention components.

d) Outcomes (for each outcome measured): frequency, description; intervention effect; control effect; statistical significance; statistical test used.

S4 Information used for data extraction from each study.
<table>
<thead>
<tr>
<th>Year</th>
<th>Country</th>
<th>Number of patients</th>
<th>Intervention Content</th>
<th>Intensity</th>
<th>Multifactorial yes/no</th>
<th>Carers participants Yes/No</th>
<th>Outcome measured</th>
<th>Excluded Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>UK</td>
<td>n = 60</td>
<td>-formulating better medication-taking routines -personalised instructions -providing evidence for patients’ medication necessity beliefs to outweigh medication concerns beliefs.</td>
<td>2 sessions (2 sessions of 30-45 minutes over 2 weeks)</td>
<td>yes</td>
<td>no</td>
<td>Adherence (electronic devices) BP</td>
<td>No anti-hypertensive medication, aphasia-Frenchay screen &lt;13/20, MMSE &lt;23, using Dosette boxes, not responsible for taking own medication.</td>
</tr>
<tr>
<td>2010</td>
<td>Canada</td>
<td>n=250</td>
<td>- rehabilitative exercise -written health passport -positive reinforcement -adult learning strategies (interactive educational sessions, participant involvement in content selection) -scheduled grocery shopping tours -cooking demonstrations</td>
<td>Regular sessions (2 x75 minutes sessions/week of exercise + 1 x 90 minutes session/week of education over 12 weeks)</td>
<td>yes</td>
<td>No</td>
<td>BP</td>
<td>Family members/carers encouraged to attend education sessions. Self-reported medication adherence</td>
</tr>
<tr>
<td>2011</td>
<td>USA</td>
<td>n=30</td>
<td>-verbal information/advice on disease/treatment. -goal settings.</td>
<td>2 sessions (2 telephone-sessions over 6 months)</td>
<td>yes</td>
<td>no</td>
<td>BP</td>
<td>Not reported</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Country</td>
<td>n</td>
<td>Interventions</td>
<td>Follow-up</td>
<td>SBP Measure</td>
<td>Exclusion Criteria</td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>---------</td>
<td>---</td>
<td>--------------------------------------------------------------------------------</td>
<td>-----------</td>
<td>-------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Cheng</td>
<td>2011</td>
<td>USA</td>
<td>268</td>
<td>- group clinics &lt;br&gt; - verbal information/advice on disease/treatment. &lt;br&gt; - self-management of disease &lt;br&gt; - optional one-on-one sessions to individualize and reinforce information</td>
<td>Regular sessions (3 group sessions over 10 month)</td>
<td>SBP</td>
<td>Yes &lt;br&gt; No Caregivers encouraged to participate in all aspects of the care Intervention</td>
<td>Hemorrhagic stroke (due to high short-term mortality rate); unable to actively participate in group clinic as judged by research team (e.g., severe global disability); language (aphasia) or cognitive difficulties causing inability to communicate understanding of the study during consent process.</td>
</tr>
<tr>
<td>Dromerick</td>
<td>2011</td>
<td>USA</td>
<td>250</td>
<td>- verbal information/advice on disease/treatment &lt;br&gt; - personalised instructions &lt;br&gt; - motivational interviewing &lt;br&gt; - practical problem solving regarding issues such as transportation, insurance, fear of medication side effects &lt;br&gt; - interaction by navigators with primary care doctors when necessary &lt;br&gt; - assistance in obtaining medications</td>
<td>Regular reviews (2 home visits + monthly telephone sessions over 12 months)</td>
<td>SBP</td>
<td>Yes &lt;br&gt; A caregiver or interested party must be available if the participant is moderately/severely disabled.</td>
<td>Severe impairment due to stroke (NIHSS &gt; 20); any medical condition that would limit participation in follow up assessments; baseline dementia per informant report (AD 828) or screening assessment (Short Blessed Memory Orientation Concentration Test29).</td>
</tr>
<tr>
<td>Goldfinger</td>
<td>2012</td>
<td>USA</td>
<td>600</td>
<td>- peer education &lt;br&gt; - verbal information/advice on disease/treatment. &lt;br&gt; - self-management of disease &lt;br&gt; - weekly action planning</td>
<td>Regular sessions (1 session/week, 90 minute duration for 6 consecutive weeks)</td>
<td>BP</td>
<td>No &lt;br&gt; Adherence to medication (self-reported, prescription-filling data)</td>
<td>People with severe aphasia or significant cognitive deficits when these conditions would impede participation in a self-management program</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>n</td>
<td>Interventions</td>
<td>Sessions</td>
<td>Compliance</td>
<td>BP</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>------</td>
<td>----</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>------------</td>
<td>-----</td>
<td>-------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>MacKenzie</td>
<td>2011</td>
<td>56</td>
<td>- verbal information/advice on disease/treatment. - motivational interviewing -self-monitoring equipment -medication dosettes</td>
<td>Regular sessions (1 telephone follow-up/month over 6 months).</td>
<td>yes</td>
<td>no</td>
<td>BP Self-reported adherence</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flemming</td>
<td>2012</td>
<td>42</td>
<td>- motivational interviewing -personalised action plan</td>
<td>Regular sessions (3 sessions and 2 telephone follow-up over 12 months)</td>
<td>yes</td>
<td>Not reported</td>
<td>BP Patients with risk factors under control</td>
<td></td>
</tr>
</tbody>
</table>

S5 Trials identified by the search strategy of which results have not yet been published. BP and SBP indicates blood pressure, respectively.
Reference list


8 Wolfe CD, Redfern J, Rudd AG, Grieve AP, Heuschmann PU, McKevitt C. Cluster randomized controlled trial of a patient and general practitioner intervention to improve the


prevent recurrence of all inner-city strokes through education randomized controlled trial.

